Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (“IVIg”)

This publication has 29 references indexed in Scilit:

• Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
  Annals of Neurology, 1998
• Immunoglobulins for Intravenous Use Inhibit TNFα CytotoxicityIn Vitro
  Immunological Investigations, 1997
• In vitro Inhibitory Activity of Tumor Necrosis Factor Alpha and lnterleukin-2 of Human Immunoglobulin Preparations
  International Archives of Allergy and Immunology, 1997
• Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
  Brain Pathology, 1996
• Inhibition of Complement‐Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties
  Scandinavian Journal of Immunology, 1995
• High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
  Journal of Clinical Investigation, 1994
• Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.
  Journal of Clinical Investigation, 1994
• The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues
  Clinical Immunology and Immunopathology, 1992
• CG‐4, A new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type‐2 astrocytes
  Journal of Neuroscience Research, 1992
• Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
  The Journal of cell biology, 1980